Genetic variations using whole-exome sequencing might predict response for neoadjuvant chemoradiotherapy in locally advanced rectal cancer
A good pathologic response to neoadjuvant chemoradiotherapy (CRT) in locally advanced rectal cancer (LARC) is associated with a better prognosis. However, there is no effective method to predict CRT response in LARC patients. Therefore, this study used whole-exome sequencing (WES) to identify novel biomarker predicting CRT benefit in LARC. Two independent tumor tissue sets were used to evaluate the genetic differences between the good CRT response group (15 patients achieved a pathologic complete response (pCR)) and the poor CRT response group (15 patients with pathologic stage III). After applying WES to the discovery set of 30 patients, additional samples (n = 67) were genotyped for candidate variants using TaqMan or Sanger sequencing for validation. Overall, this study included a total of 97 LARC patients. In the discovery and validation set, there was no known genetic mutation to predict response between two groups, while five candidate variants (BCL2L10 rs2231292, DLC1 rs3816748, DNAH14 rs3105571, ITIH5 rs3824658, and RAET1L rs912565) were found to be significantly associated with pCR. In the dominant model, the GC/CC genotype of DLC1 rs3816748 (p = 0.032), AC/CC genotype of DNAH14 rs3105571 (p = 0.009), and TT genotype of RAET1 rs912565 (p < 0.0001) were associated with a higher pCR rate. In the recessive model, BCL2L10 rs2231292 (p = 0.036) and ITIH5 rs3824658 (p = 0.003) were significantly associated with pCR. In the co-dominant model, 4 candidate variants (DLC1 rs3816748, DNAH14 rs3105571, ITIH5 rs3824658, and RAET1L rs912565) were significantly correlated with pCR. However, none of the candidate variants was associated with relapse-free or overall survival. The present results suggest that genetic variations of the BCL2L10 rs2231292, DLC1 rs3816748, DNAH14 rs3105571, ITIH5 rs3824658, and RAET1L rs912565 genes can be used as biomarkers predicting the CRT response for patients with LARC.
KeywordsNext-generation sequencing Whole-exome sequencing Pathologic complete response Neoadjuvant chemoradiotherapy Locally advanced rectal cancer
This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (2014R1A5A2009242) and Korean Cancer Foundation (K20170519).
Compliance with ethical standards
Conflict of interest
The authors declared no conflicts of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the Kyungpook National University Hospital Institutional Review Board (IRB).
Informed consent was obtained from all individual participants included in the study.
- 2.Maas M, Nelemans PJ, Valentini V, Das P, Rodel C, Kuo LJ, et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol. 2010;11(9):835–44. https://doi.org/10.1016/s1470-2045(10)70172-8.CrossRefPubMedGoogle Scholar
- 3.Molinari C, Matteucci F, Caroli P, Passardi A. Biomarkers and molecular imaging as predictors of response to neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer. Clin Colorectal Cancer. 2015;14(4):227–38. https://doi.org/10.1016/j.clcc.2015.05.014.CrossRefPubMedGoogle Scholar
- 4.Kim CW, Yu CS, Yang SS, Kim KH, Yoon YS, Yoon SN, et al. Clinical significance of pre- to post-chemoradiotherapy s-CEA reduction ratio in rectal cancer patients treated with preoperative chemoradiotherapy and curative resection. Ann Surg Oncol. 2011;18(12):3271–7. https://doi.org/10.1245/s10434-011-1740-1.CrossRefPubMedGoogle Scholar
- 7.Lips EH, Michaut M, Hoogstraat M, Mulder L, Besselink NJ, Koudijs MJ, et al. Next generation sequencing of triple negative breast cancer to find predictors for chemotherapy response. Breast Cancer Res. 2015;17(1):134. https://doi.org/10.1186/s13058-015-0642-8.CrossRefPubMedPubMedCentralGoogle Scholar
- 8.Park K, Choi MK, Jung HH, Do IG, Lee KH, Ahn T, et al. Molecular characterization of patients with pathologic complete response or early failure after neoadjuvant chemotherapy for locally advanced breast cancer using next generation sequencing and nCounter assay. Oncotarget. 2015;6(27):24499–510. https://doi.org/10.18632/oncotarget.4119.CrossRefPubMedPubMedCentralGoogle Scholar
- 9.Crumley SM, Pepper KL, Phan AT, Olsen RJ, Schwartz MR, Portier BP. Next-generation sequencing of matched primary and metastatic rectal adenocarcinomas demonstrates minimal mutation gain and concordance to colonic adenocarcinomas. Arch Pathol Lab Med. 2016;140(6):529–35. https://doi.org/10.5858/arpa.2015-0261-SA.CrossRefPubMedGoogle Scholar
- 17.Kim JC, Ha YJ, Roh SA, Cho DH, Choi EY, Kim TW, et al. Novel single-nucleotide polymorphism markers predictive of pathologic response to preoperative chemoradiation therapy in rectal cancer patients. Int J Radiat Oncol Biol Phys. 2013;86(2):350–7. https://doi.org/10.1016/j.ijrobp.2012.12.018.CrossRefPubMedGoogle Scholar
- 19.Dreussi E, Pucciarelli S, De Paoli A, Polesel J, Canzonieri V, Agostini M, et al. Predictive role of microRNA-related genetic polymorphisms in the pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients. Oncotarget. 2016;7(15):19781–93. https://doi.org/10.18632/oncotarget.7757.CrossRefPubMedPubMedCentralGoogle Scholar
- 24.Chang H, Rha SY, Jeung HC, Jung JJ, Kim TS, Kwon HJ, et al. Identification of genes related to a synergistic effect of taxane and suberoylanilide hydroxamic acid combination treatment in gastric cancer cells. J Cancer Res Clin Oncol. 2010;136(12):1901–13. https://doi.org/10.1007/s00432-010-0849-0.CrossRefPubMedGoogle Scholar
- 25.Antoun A, Vekaria D, Salama RA, Pratt G, Jobson S, Cook M, et al. The genotype of RAET1L (ULBP6), a ligand for human NKG2D (KLRK1), markedly influences the clinical outcome of allogeneic stem cell transplantation. Br J Haematol. 2012;159(5):589–98. https://doi.org/10.1111/bjh.12072.CrossRefPubMedGoogle Scholar
- 29.Rose M, Gaisa NT, Antony P, Fiedler D, Heidenreich A, Otto W, et al. Epigenetic inactivation of ITIH5 promotes bladder cancer progression and predicts early relapse of pT1 high-grade urothelial tumours. Carcinogenesis. 2014;35(3):727–36. https://doi.org/10.1093/carcin/bgt375.CrossRefPubMedGoogle Scholar
- 30.Kloten V, Rose M, Kaspar S, von Stillfried S, Knuchel R, Dahl E. Epigenetic inactivation of the novel candidate tumor suppressor gene ITIH5 in colon cancer predicts unfavorable overall survival in the CpG island methylator phenotype. Epigenetics. 2014;9(9):1290–301. https://doi.org/10.4161/epi.32089.CrossRefPubMedPubMedCentralGoogle Scholar
- 31.Veeck J, Chorovicer M, Naami A, Breuer E, Zafrakas M, Bektas N, et al. The extracellular matrix protein ITIH5 is a novel prognostic marker in invasive node-negative breast cancer and its aberrant expression is caused by promoter hypermethylation. Oncogene. 2008;27(6):865–76. https://doi.org/10.1038/sj.onc.1210669.CrossRefPubMedGoogle Scholar